| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
DiaMedica Therapeutics Inc.$7.67
-0.04 (-0.52%)
C 45Pipeline Score Fair Value Biotech · Clinical
Market Cap
318.45 M
EPS
-0.71
P/E Ratio
-
Value Trade
1.06 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
7.99 M
Operating CF
-9.08 M
Total Assets
53.08 M
Total Liabilities
53.08 M
Equity
47.23 M
D/E Ratio
12,345
-5.14 %
Week
-8.51 %
1 Month
-29.56 %
3 Month
-18.26 %
6 Month
-19.59 %
5 Year
-82.32 %
All Time
Cash Data
Cash Position
51.33 M
Monthly Burn
3.03 M
Runway
15.1 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
163.89 K
52 Week Range
3.48 - 10.42
% held by Insiders
49.77 %
% held by Institutions
21.67 %
Enterprise Value
267.33 M
Total Shares
53.88 M
Short %
21.42 %
Float Shares
24.30 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for DiaMedica Therapeutics Inc.
94Total events
0Upcoming
10Tier-1 (high impact)
2016 – 2026Coverage
Event history 94
Jun 23, 2026
▲First Patient DosedDM199Trial
First patients dosed in Phase 2 trial of DM199 for Fetal Growth Restriction
Fetal Growth Restrictionsource ↗
Jun 16, 2026
◆FDA Feedback ReceivedDM199FDA Meeting
FDA feedback on DM199 preeclampsia nonclinical program
preeclampsiasource ↗
Jun 4, 2026
◆Oral PresentationPresentation
Corporate Presentation at Jefferies Global Healthcare Conference 2026
May 20, 2026
▲Enrollment MilestoneDM199Trial
75% enrollment milestone in ReMEDy2 Phase 2/3 acute ischemic stroke trial
acute ischemic strokesource ↗
May 19, 2026
◆Oral PresentationPresentation
DiaMedica to participate in RBC Capital Markets Global Healthcare Conference fireside chat
May 7, 2026
◆Quarterly UpdateCorporate
First Quarter 2026 Financial Results Release and Business Update Conference Call
Mar 11, 2026
◆Oral PresentationPresentation
Leerink Partners Global Healthcare Conference Company Presentation
Mar 10, 2026
◆Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference Fireside Chat
Mar 5, 2026
▲IND ClearanceDM199IND
Health Canada clearance to initiate Phase 2 study of DM199 in early-onset preeclampsia
early-onset preeclampsiasource ↗
Drug Pipeline Intelligence
C45
Pipeline Score $408M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.3x
rNPV / MCap Top 67%
Micro Cap (rank 302 of 911)
Percentile RankDiaMedica Therapeutics Inc. carries a moderate pipeline score (45/100), with $2.3B risk-adjusted pipeline value, led by DM199 in Chronic Kidney Disease (Phase 1), across $172B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM199 Small molecule | Kidney Diseases | Phase 2 | NCT04123613 | 16% | $2.0B | COMPLETED | 79 | - | - | Mar 16, 2022 | - | Mar 31, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
DM199 | Chronic Kidney Disease | Phase 1b | 2019-08-13 | Nitric Oxide: average increase of 35.2%; Prostaglandin E2: average increase of 41.2%; e GFR: average increase of 4.08 mL/min/1732; UACR: average decrease of 18.7% Read More | DiaMedica Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update Read More | |
DM199 | Chronic Kidney Disease | Phase 1b | 2019-08-13 | Nitric Oxide: average increase of 35.2%; Prostaglandin E2: average increase of 41.2%; e GFR: average increase of 4.08 mL/min/1732; UACR: average decrease of 18.7% Read More | DiaMedica Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update Read More | |
DM199 | Chronic Kidney Disease | Phase 1b | 2019-08-13 | Nitric Oxide: average increase of 35.2%; Prostaglandin E2: average increase of 41.2%; e GFR: average increase of 4.08 mL/min/1732; UACR: average decrease of 18.7% Read More | DiaMedica Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DMAC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DMAC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
DMAC▲ +6.6%on this news
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
DiaMedica Therapeutics has announced the dosing of the first patients in a Phase 2 trial for DM199, aimed at treating fetal growth restriction. This marks a significant step in their clinical development process. Further details regarding the trial's objectives and expected outcomes were not provided.
Read more →DMACDiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
DiaMedica has received feedback from the FDA regarding its nonclinical program for DM199, which is aimed at addressing preeclampsia. The details of the feedback and its implications for the program have not been disclosed. This interaction with the FDA is a crucial step in the development process for DM199.
Read more →DMACDiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
DiaMedica Therapeutics is scheduled to present at the Jefferies Global Healthcare Conference in 2026. The event is expected to provide insights into the company's developments and future plans. Further details about the presentation and topics to be discussed have not been disclosed.
Read more →DMACDiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Therapeutics has announced that it has achieved a 75% enrollment milestone in its ReMEDy2 Phase 2/3 trial for acute ischemic stroke. This progress indicates a strong commitment to advancing the study, which aims to evaluate the safety and efficacy of its treatment. The milestone is a crucial step towards completing the trial and potentially bringing new options to patients.
Read more →DMACDiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
DiaMedica Therapeutics is set to participate in the 2026 RBC Capital Markets Global Healthcare Conference. This event highlights the company's ongoing engagement with investors and stakeholders in the healthcare sector. Further details about their participation or agenda have not been disclosed.
Read more →DMACDiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
DiaMedica Therapeutics has released its financial results for the first quarter of 2026, along with key business highlights. However, the article does not provide specific details regarding the financial performance or business developments. The lack of substantial information limits the analysis of the company's current status.
Read more →DMACDiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
DiaMedica Therapeutics Inc. will release its first quarter 2026 financial results on May 6, 2026. A live conference call is scheduled for May 7, 2026, at 8:00 AM EDT to discuss these results and provide a business update. The company focuses on innovative treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke.
Read more →DMACDiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
DiaMedica Therapeutics has reported its financial results for the full year 2025, along with key business highlights. The details of the financial performance and strategic initiatives were discussed, although specific figures and outcomes were not provided in the article. The report aims to inform stakeholders about the company's current status and future direction.
Read more →DMAC▲ +7.8%on this news
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
DiaMedica Therapeutics Inc. will release its full-year 2025 financial results on March 30, 2026, after market close. The company will also host a conference call on March 31, 2026, at 7:00 AM CT to provide a business update. This event highlights DiaMedica's ongoing commitment to transparency and investor relations.
Read more →DMACDiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
DiaMedica Therapeutics has received Health Canada clearance to initiate a Phase 2 study of DM199 for early-onset preeclampsia. The trial, set to begin in 2026, will evaluate the safety and efficacy of DM199 in pregnant women. This regulatory approval follows promising results from an earlier trial in South Africa, highlighting the need for new treatments in this area.
Read more →DMACDiaMedica Therapeutics to Participate in Upcoming March 2026 Investor Conferences
DiaMedica Therapeutics Inc. will participate in three investor conferences in March 2026. CEO Rick Pauls and Chief Medical Officer Julie Krop will engage in discussions at the TD Cowen Healthcare Conference and Barclays Global Healthcare Conference, while Pauls will also present at the Leerink Partners Global Healthcare Conference. The company focuses on treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke.
Read more →DMACDiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
DiaMedica Therapeutics Inc. will participate in three upcoming investor conferences, showcasing their commitment to engaging with the investment community. CEO Rick Pauls and Chief Medical Officer Julie Krop will lead discussions on their innovative treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke. These events are scheduled for March 2026 in Boston and Miami.
Read more →DMACDiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 16, 2026
DiaMedica Therapeutics Inc. announced the granting of stock options to a newly hired non-executive employee as an inducement for accepting employment. This grant, totaling 50,000 shares, complies with Nasdaq Listing Rule 5635(c)(4) and is part of the company's compensation strategy. The options have a ten-year term and will vest over time, contingent on the employee's continued service.
Read more →DMACDiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019
DiaMedica Therapeutics Inc. will participate in the Lake Street Capital Markets 3rd Annual Best Ideas Growth Conference on September 12, 2019. CEO Rick Pauls will engage in one-on-one meetings with investors throughout the day. The conference aims to connect institutional investors with dynamic public growth companies.
Read more →DMACDiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference
DiaMedica Therapeutics Inc. will present at the 2019 Dougherty & Co. Institutional Investor Conference in Minneapolis. CEO Rick Pauls will host one-on-one meetings with institutional investors. The company is focused on developing treatments for chronic kidney diseases and neurological disorders, with ongoing studies in acute ischemic stroke and chronic kidney disease.
Read more →DMACDiaMedica Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update
DiaMedica Therapeutics reported its Q2 2019 financial results and provided updates on its clinical trials. The company completed enrollment in a Phase Ib study of DM199 for chronic kidney disease, showing positive interim results. Additionally, a protocol for a Phase II study targeting IgA Nephropathy has been submitted to the FDA. Financially, the company experienced increased R&D expenses and operating losses, but has regained worldwide rights for DM199.
Read more →DMACDiaMedica Therapeutics to Present at the 2019 Intellisight Investor Conference on August 14, 2019
DiaMedica Therapeutics Inc. will present at the 2019 Intellisight Conference on August 14. CEO Rick Pauls will discuss the company's focus on chronic kidney diseases and neurological disorders. DiaMedica is currently conducting a phase II study in acute ischemic stroke and a phase Ib study in chronic kidney disease.
Read more →DMACDiaMedica Therapeutics to Report Second Quarter 2019 Financials and Provide a Business Update August 13, 2019
MINNEAPOLIS, Aug. 08, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2019 financial results will be released after the markets close on Tuesday, August 13th. DiaMedica will host a live conference call on Wednesday, Augu
Read more →DMACDiaMedica Therapeutics Announces Interim Results from Phase 1b Trial of DM199 in Chronic Kidney Disease Participants
DiaMedica Therapeutics announced positive interim results from its Phase 1b trial of DM199 in patients with chronic kidney disease (CKD). The study involved 28 evaluable participants and demonstrated that DM199 was safe and well tolerated, with no serious adverse events reported. Early signals of drug activity were observed, supporting the advancement of DM199 to Phase II trials.
Read more →DMACDiaMedica Therapeutics to Present at the 16th Annual Craig-Hallum Institutional Investor Conference on May 29, 2019
DiaMedica Therapeutics Inc. will present at the 16th Annual Craig-Hallum Institutional Investor Conference on May 29, 2019. The event will take place at the Depot Renaissance Minneapolis Hotel, where management will hold one-on-one meetings with investors. DiaMedica specializes in developing treatments for chronic kidney diseases and neurological disorders.
Read more →DMACDiaMedica Therapeutics Announces Formation of Scientific Advisory Board for Kidney Disease
DiaMedica Therapeutics has established a Scientific Advisory Board to support the development of DM199, a treatment for chronic kidney disease (CKD). The board comprises experts in CKD and hypertension, who will collaborate with the company's management to advance DM199's clinical development. This initiative reflects the company's commitment to improving patient outcomes in CKD.
Read more →DMACDiaMedica Therapeutics Announces First Quarter 2019 Financial Results and Provides Business Update
Phase Ib study of DM199 in Chronic Kidney Disease nearing full enrollment Completion of new cGMP manufacturing run of DM199 Conference call with management tomorrow, May 14, 2019 at 7am CT MINNEAPOLIS, May 13, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC)
Read more →DMACDiaMedica Therapeutics to Report First Quarter 2019 Financials and Provide an Update on Development Programs on May 14, 2019
DiaMedica Therapeutics Inc. will release its first quarter 2019 financial results on May 13, 2019, after market close. A conference call is scheduled for May 14, 2019, at 7:00 am CT, where management will discuss the financial results and provide a business update. The call will be available for playback on their website.
Read more →DMACDiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting
MINNEAPOLIS, April 30, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that Dr Harry Alcorn, its Chief Medical Officer will be presenting “CKD New Therapeutic Development: DM199 for Chronic Kidney Diseas
Read more →DMACDiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update
Dosed first patients in Phase Ib study of DM199 in Chronic Kidney Disease patients under an IND accepted by the FDA in 2018; Plan to initiate Phase II studies in 2H 2019 Acute ischemic stroke Phase II REMEDY clinical trial expanded from 60 to 100 patients Initial public offerin
Read more →DMACDiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call
MINNEAPOLIS, March 18, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its 2018 financial results will be released after market close on Tuesday, March 19th. DiaMedica’s management will host a live conference call on Wednesday, March 20th
Read more →DMACDiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019
MINNEAPOLIS, March 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019, at The Ritz Carlton, Laguna Niguel in Dana Point, CA. DiaMedica’s President and CEO, Rick Pauls
Read more →DMACDiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
MINNEAPOLIS, Feb. 14, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that it has initiated dosing patients with chronic kidney disease (“CKD”) in a Phase Ib clinical study evaluating DM199. The Phase 1
Read more →DMACDiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders
MINNEAPOLIS, Jan. 22, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announces the publication of a paper titled “Human Tissue Kallikrein In The Treatment Of Acute Ischemic Stroke” in the peer reviewed journal, Therapeutic Advances in Neurological Disorders (
Read more →DMACDiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange
MINNEAPOLIS, Jan. 09, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) (TSX-V: DMA), a clinical stage biopharmaceutical company, announced today that it has applied to voluntarily delist its voting common shares from the TSX Venture Exchange. The Company’s com
Read more →DMACDiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
MINNEAPOLIS, Jan. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSX-V:DMA) announced today that the U.S. Food and Drug Administration ("FDA") has accepted DiaMedica’s Investigational New Drug application ("IND") for the initiation of a Phas
Read more →DMACDiaMedica Closes Public Offering in the United States
MINNEAPOLIS, Dec. 11, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica” or the “Company”) (NASDAQ:DMAC; TSXV:DMA), a clinical stage biopharmaceutical company, announced today that it has completed an underwritten initial public offering in the United States (the “
Read more →DMACDIAMEDICA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING AND NASDAQ LISTING
MINNEAPOLIS, Dec. 07, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSX‑V:DMA), a clinical stage biopharmaceutical company, announced today the pricing of its initial public offering in the United States of 4,100,000 of its common shares at a p
Read more →DMACDiaMedica Therapeutics Has Applied to List its Common Shares on Nasdaq, Announces Share Consolidation
MINNEAPOLIS, Nov. 12, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX Venture:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, announced today that it has applied to list its common shares on The Nasdaq Capital Market. In connection with the planned U.S.
Read more →DMACDiaMedica Therapeutics Announces Results From Annual General and Special Meeting of Shareholders
MINNEAPOLIS, Nov. 06, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX-V:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, today announced the voting results from its Annual General and Special Shareholders Meeting held on November 6, 2018. A total of 51.4%
Read more →DMACDiaMedica Therapeutics and Ahon Pharma, a Fosun Pharma Portfolio Company, Announces Signing of License Agreement for DM199 in China for Acute Ischemic Stroke
MINNEAPOLIS and SHANGHAI, China, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Ahon Pharmaceutical Co Ltd.(Ahon Pharma), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd, (Fosun Pharma, HKG: 02196 and SHA: 600196) and DiaMedica Therapeutics Inc. (TSX Venture: DMA and OTCQB: DMC
Read more →DMACDiaMedica Therapeutics Announces the Appointment of Dr. Harry Alcorn Jr. as Chief Medical Officer
MINNEAPOLIS, Sept. 05, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company” and “DiaMedica”) (TSX-V:DMA) (OTCQB:DMCAF) announces the recent appointment of Harry Alcorn Jr. Pharm.D. as Chief Medical Officer where he will oversee global clinical development and regul
Read more →DMACDiaMedica Issues Stock Option Grant
MINNEAPOLIS, Aug. 23, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the "Company") (TSX VENTURE:DMA) (OTCQB:DMCAF), today announces it has issued 600,000 stock options to new employees and advisors of the Company. The options were issued at $0.52 per share and have a ten
Read more →DMACDiaMedica Announces Positive Results From FDA Meeting on Planned Clinical Trial in Patients with Chronic Kidney Disease
DiaMedica has received final minutes from Type B meeting with the US FDA DiaMedica preparing to submit an IND to initiate DM199 clinical study in patients with chronic kidney disease in the US MINNEAPOLIS, May 03, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica
Read more →DMACDiaMedica Issues Stock Option Grants
MINNEAPOLIS, April 17, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the "Company") (TSX-V:DMA) (OTCQB:DMCAF), today announced the issuance of 2,551,000 stock options to various officers and directors of the Company. The options were issued at $0.56 per share and have a
Read more →DMACDiaMedica Therapeutics Announces Appointment of Scott Kellen as Chief Financial Officer
MINNEAPOLIS, April 05, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the appointment of Mr. Scott Kellen as Chief Financial Officer and Corporate Secretary. “We are extremenly pleased to welcome Scott to Dia
Read more →DMACDiaMedica Therapeutics Announces Final Closing of Private Placement
MINNEAPOLIS, March 29, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company” and “DiaMedica”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the successful completion of the second and final tranche of its previously announced offering of units (the “Units”) for a
Read more →DMACDiaMedica Therapeutics Announces Closing of Private Placement
MINNEAPOLIS, March 20, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the successful completion of the first closing of a private placement for aggregate gross proceeds of USD$3.8 million (the “Offering”). Th
Read more →DMACDiaMedica Announces First Enrollment in its PHASE 2 “REMEDY” TRIAL for Acute Ischemic Stroke
DM199 may offer an effective and safe treatment with a significantly longer treatment window (24 hours) compared to the current standard of care REMEDY trial lead by prominent neurologist Dr. Bruce Campbell, its Principal Investigator MINNEAPOLIS, Feb. 22, 2018 (GLOBE NEWSWIRE)
Read more →DMACDiaMedica to Present at the 14th Annual Noble Investor Conference
MINNEAPOLIS, Jan. 29, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSXV:DMA) (OTCQB:DMCAF), today announced that Mr. Rick Pauls, its President and CEO, will present at Noble Capital Markets’ Fourteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida o
Read more →DMACDiaMedica Letter to Shareholders
MINNEAPOLIS, Jan. 18, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (TSX VENTURE:DMA) (OTCQB:DMCAF), provides corporate update. As we enter into 2018, we wanted to thank you, our shareholders, for your continued support. Looking back, 2017 was a momentous ye
Read more →DMACDiaMedica Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
MINNEAPOLIS, Dec. 21, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX-V:DMA) (OTCQB:DMCAF) (the “Company”), today announced that at its Annual General and Special Meeting (the “Meeting”) of shareholders held on December 21, 2017, the shareholders approved all the resolu
Read more →DMACDiaMedica Therapeutics Completes Non-Brokered Private Placement
MINNEAPOLIS, Dec. 18, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) announced today the closing of its previously announced non-brokered private placement raising total gross proceeds of approximately CAD$1.2 million (approximately
Read more →DMACDiaMedica Therapeutics Announces Non-Brokered Private Placement
MINNEAPOLIS, Dec. 13, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF), announces that, subject to TSX Venture Exchange approval, it is undertaking a non-brokered private placement for gross proceeds of approximately CAD$1 million (ap
Read more →DMACDiaMedica Therapeutics Announces Ethics Committee Clearance at First Site to Initiate REMEDY Phase 2 Trial for Acute Ischemic Stroke
MINNEAPOLIS, Nov. 22, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX Venture:DMA) (OTCQB:DMCAF), announced it has received ethics committee approval to initiate the first clinical site for its Phase 2 REMEDY clinical trial with DM199 (recombinant human
Read more →DMACDiaMedica Accelerates Warrant Expiry Date
MINNEAPOLIS, Nov. 20, 2017 (GLOBE NEWSWIRE) -- DiaMedica (TSX-V:DMA) today on behalf of the board of directors announces that in accordance with the terms of the warrant indenture for warrants issued on April 18, 2017, the company has provided written notice to holders of such wa
Read more →DMACDiaMedica Therapeutics Announces Publication of Positive Clinical Results for DM199 in the International Journal of Clinical Trials
MINNEAPOLIS, Nov. 07, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX Venture:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company focused on improving the lives of patients with neurological and kidney diseases associated with low KLK1 levels,
Read more →DMACDiaMedica Announces Dr. Robert Stanton as Scientific Advisor for Upcoming Chronic Kidney Disease Trials
MINNEAPOLIS, Oct. 31, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “DiaMedica”) (TSX Venture:DMA) (OTCQB:DMCAF) is pleased to announce that Dr. Robert Stanton, Chief of the Kidney and Hypertension Section and a Principal Investigator of Vascular Cell Biology at Josli
Read more →DMACDiaMedica Therapeutics Announces the Early Exercise of Warrants from Strategic Investor
MINNEAPOLIS, Oct. 27, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX Venture:DMA) (OTCQB:DMCAF), announces the receipt of approximately USD$605,263 in gross proceeds from the early exercise of 2,631,579 April 2017 warrants at USD$0.23 (CAD$0.31) per sha
Read more →DMACDiaMedica Announces the Initiation of Phase 2 Trial Evaluating DM199 (Recombinant Human KLK1) in Patients with Acute Ischemic Stroke
DM199 may offer substantial benefits to stroke patients with a drug treatment window of 24 hours post-stroke The REMEDY trial is designed to assess the clinical effect of DM199 for acute ischemic stroke with the endorsement from the Australasian Stroke Clinical Trials Network (“
Read more →DMACDiaMedica Therapeutics Completes Private Placement With U.S. Based Family Office
MINNEAPOLIS, MINNESOTA--(Marketwired - April 18, 2017) - DiaMedica Therapeutics Inc. (the "Company") (TSX VENTURE:DMA)(OTCQB:DMCAF), a biopharmaceutical company focused on the development of DM199 (recombinant human KLK1), is pleased to announce it has completed a non-brokered pr
Read more →DMACDiaMedica Announces Name Change to DiaMedica Therapeutics Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Dec. 23, 2016) - DiaMedica Inc. (the "Company") (TSX VENTURE:DMA)(OTCQB:DMCAF) announced today it will change its name to DiaMedica Therapeutics Inc. "We are strategically focused on developing therapeutics for patients with unmet medical n
Read more →Competitive Position
How DMAC ranks across every disease it competes inCompetitive Position is a premium feature
See how DMAC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial